anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340272A vaccine. The first vaccine dose was administered intramuscularly in the deltoid region of the non-dominant arm at Day 0, and the second vaccine dose was administered intramuscularly in the deltoid region of the dominant arm at Day 21.
Participants with histologically confirmed prostate cancer, that is either newly diagnosed OR progressive as defined by standard PCWG3 criteria. Patients w ill remain on study until 30 days after their last PSMA imaging timepoint required by their companion therapeutic protocol.
If clorazepate dipotassium is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed. Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition. Clinical studies have shown increased sedation with concurrent hypnotic medications. The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.

If clorazepate dipotassium tablets are used to treat anxiety associated with somatic disease states, careful attention must be paid to possible drug interaction with concomitant medication.

In bioavailability studies with normal subjects, the concurrent administration of antacids at therapeutic levels did not significantly influence the bioavailability of clorazepate dipotassium tablets.
<P>PROBLEM TO BE SOLVED: To provide a medical material which can securely obstruct accretion regardless of tissue and position.  <P>SOLUTION: The medical material for obstructing accretion has a skeleton as a structure comprising a biocompatible base material and containing more than 40 wt.% of polyol therein. As the biocompatible base material, an in vivo non-decomposing absorptive substance selected from polyester, polyurethane, polyamide, silicone resin, and fluorine containing polymer, or a base material selected from such as polysaccharide such as collagen, cellulose, carboxymethyl cellulose, chitin, chitosan, starch, amylose, amylopectin, dextrin and in vivo decomposing absorptive substances such as polyvinyl alcohol, polyethylene glycol, polycaprolactone, polylactic acid, polyglycollic acid, polycaproic acid, polymethylene carbonate are preferable. As the polyol, polyethylene glycol, xylitol, sorbitol, glycerine, etc. are preferable.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Due to the stepped wedge design of the study, one group in each centre will not receive the intervention procedure detailed above until week seven. The control groups shall be given information about the study at baseline and informed that they will receive the intervention 6 weeks later.
PROBLEM TO BE SOLVED: To effectively utilize a pollutant of pickled ume pickling water discharged as pollution waste water heretofore by separating a pickled ume salt water processing soln. being waste in pickled ume processing from a pickled ume to desalt and neutralize the same and further bleaching and discoloring this soln. and further desalting and purifying the soln. to form a waste soln. and adding this waste soln. to health food, a health drink, icecrem, an ice confectionary or bread to utilize the same therein or using the waste soln. in a plating soln. or atopic dermatitis bathing agent treatment. SOLUTION: Pickling water 9 separated from a pickled ume is desalted by a diaphragm electrolytic device 14 and alkali pickling water being a byproduct is added to a raw soln. to neutralize the same and the neutral soln. is anodically oxidized to be diluted with water to be discharged to improve pollution waste water and, further, this electrolytic treatment soln. is effectively utilized in food, feed medicines, a bathing agent and plating soln. to enhance the productivity of a pickled ume. The waste pickled ume picking soln. is subjected to electrolytic treatments 13, 14, 15 to purify pollution waste water and a pickled ume pickling soln. is utilized in health food, a health drink, bread, icecream, a bathing agent and feed to achieve rationalization of the production of synthetic pickled ume processing and the cost required for the purification of waste water conventionally is saved.
Guidelines recommend intravenous loop diuretics as first-line therapy for patients hospitalized with acute heart failure (AHF) and volume overload. Additional agents can be used for augmentation, but there is limited guidance on agent selection. The study objective was to determine if chlorothiazide or metolazone is associated with differences in diuretic efficacy or safety in loop diuretic-resistant patients with AHF and renal dysfunction (eGFR <45 mL/min/1.73 m²). We conducted a multicenter, retrospective cohort study of patients hospitalized with AHF and renal dysfunction who received metolazone or chlorothiazide in addition to intravenous loop diuretics. The primary end point was a comparison of 24-hour urine output (UOP) between the 24 hours before and after thiazide administration. Secondary and safety end points included weight change, requirement for vasopressors or inotropes, electrolyte abnormalities, and changes in renal function. A total of 221 patients were included. The mean daily diuretic doses were chlorothiazide 632 mg and metolazone 7 mg. The mean 24-hour UOP increased more among chlorothiazide-treated (from 1668 mL to 3826 mL) versus metolazone-treated patients (from 1672 mL to 2834 mL) ( P < 0.001) after the addition of the second diuretic. Statistically significant reductions in serum creatinine were observed in the chlorothiazide group following 72 hours of treatment ( P = 0.016). More hypomagnesemia was observed in the chlorothiazide group; no differences in other electrolytes or changes in weight were observed. Overall, chlorothiazide was associated with a greater increase in 24-hour UOP than metolazone without an excess of potassium or serum creatinine derangements. However, weight changes did not differ significantly between groups. Future prospective studies are needed to confirm potential differences in diuretic response and safety.
After recording demographic data, "Trunk control measurement scale" (TCMS) to evaluate trunk control, "Gorge motor function classification system" (GMFCS) to measure gross motor functions, "Pediatric Disability Assessment Inventory" (PDI) to evaluate activities of daily living, balance 'Pediatric Berg Balance Scale' was used to evaluate functional capacities and '2-minute walking test' was used to evaluate functional capacities. In addition, respiratory muscle strength was evaluated with maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) measurements.
This is an open-label, single-arm, multicenter, Phase 2 study of anagrelide CR in subjects with an MPN-related thrombocytosis. Eligible subjects will include those who have not been previously treated for thrombocytosis or have not received platelet-lowering therapy for at least 2 weeks prior to study treatment. Each subject will receive anagrelide CR at a starting dose of 0.5 mg b.i.d. (1.0 mg/day), and is anticipated to continue study treatment for at least 24 weeks. Subjects who have achieved clinical benefit in the opinion of the Investigator and who are tolerating the study drug may continue study treatment until they develop unacceptable toxicity or other discontinuation criteria have been met.

The primary efficacy endpoint will be the proportion of subjects who achieve a platelet response (CR or PR). The safety and tolerability of study treatment will be assessed by the frequency and severity of adverse events as determined by NCI Common Terminology Criteria for Adverse Events (CTCAE) v 4.03. The PK profile of anagrelide CR will be assessed at the initial (0.5mg b.i.d.) and final titrated dose levels.
The present invention relates to a Chinese herbal medicine compound used for preparing a non-dependence anodyne and a preparation thereof. The components comprises: barrenwort, asarum, eucommia, tuckahoe, codonopsis pilosula, fried Chinese date kernel, yam, cinnamon, paeonia lactiflora pallas, baked ginger, nutagrass flatsedge rhizome, dried old orange peel, astraolylis lancea formalyrata, hawthorn, burnt hawthorn and fleece-flower root. The optimal preparation is medicinal broth. The compound has efficiency of supporting correctitude, eliminating evil, dredging the channel, benefiting vital energy and nourishing blood, and can improve the microcirculation of core and vascular systems, repair impaired organs and enhance immunity. The present invention can reach the effect of rapid acesodyne without a side effect, and dependence is not generated. The compound is mainly applied to middle and terminal cancer pain and withdrawal period pain of drug dependence patients.
Disclosed is a conjugate of a protein having substantial L-asparagine aminohydrolase activity and polyethylene glycol. In particular, the polyethylene glycol has a molecular weight less than or equal to about 5000 Da and the protein is an L-asparaginase from  Erwinia . The conjugate of the invention has shown superior properties such as maintenance of a high level of in vitro activity and an unexpected increase in half-life in vivo. Also disclosed are methods of producing the conjugate and use of the conjugate in therapy. In particular, a method is disclosed for use of the conjugate in the treatment of cancer, particularly Acute Lymphoblastic Leukemia (ALL). More specifically, a method is disclosed for use of the conjugate as a second line therapy for patients who have developed hypersensitivity or have had a disease relapse after treatment with other L-asparaginase preparations.
The invention discloses an application of esculentoside A in preparing a myocardial infarction protection medicament. The esculentoside A has obvious protective effect on HL-1 cells damaged by hypoxia in vitro. The esculentoside A can effectively improve the increase of ROS level in HL-1 cells and the decrease of cell membrane potential caused by anoxia, and enhance the anti-oxidative stress capability of cell mitochondria. The esculentoside A has obvious down-regulation effect on the increase of LDH, cTnI, CK-MB and MDA caused by myocardial infarction, and has obvious up-regulation effect on SOD. The electrocardiogram and cardiac ultrasound results show that the esculentoside A has a protective effect on cardiac function damage caused by MI, and can improve the cardiac function of myocardial infarction mice to a certain extent. The esculentoside A can protect the heart from histopathological changes caused by blood vessel ligation to a certain extent, effectively slow down the myocardial infarction process caused by ligation, reduce the degree of myocardial fibrosis, reduce the infarction area, effectively reduce the myocardial infarction degree of mice and relieve the myocardial ischemia condition after myocardial infarction.
NEW MATERIAL:A substance, consisting of an acidic protein, exhibiting 30,000-45,000 molecular weight by analysis using gel filtration chromatography and having 4.5-6.5 isoelectric point. USE:A preventing or treating agent for diseases caused by vascular thrombosis, e.g. cardiac infarction, etc., and diagnostic agent for cancer. PREPARATION:A villous epithelial cancerated strain cell is initially cultivated using an PRMI1640 culture medium containing newly born calf blood serum, penicillin and streptomycin in CO2 at 37 deg.C for 4-10 days. The multiplied cells are washed and lactic acid Ringer solution containing no added blood serum is added thereto and shaked at 4 deg.C for 3-10hr to afford a crude solution containing a vascular neogenetic factor. The above-mentioned crude solution is finally treated with an ultrafiltration membrane, adsorbed and desorbed from an anion exchanger to provide the purified aimed substance.
In group B anesthesia will be induced by Propofol (2mg/kg), Fentanyl (2mcg/kg)and Cisatracurium (0.15mg/kg). Anesthesia will be maintained by Sevoflurane, oxygen (Fi=40%) and air and boluses of Fentanyl (50mcg). additional boluses of Cisatracurium (0.02mg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum acetaminophen 1g will be administered.
BACKGROUND: Preconception or antenatal lifestyle interventions in women with obesity may prevent adverse cardiovascular outcomes in the child, including cardiac remodelling. We undertook a systematic review of the existing data to examine the impact of randomised controlled trials of lifestyle interventions in pregnant women with obesity on offspring cardiac remodelling and related parameters of cardiovascular health.
METHODS: This review was registered with PROSPERO (CRD42023454762) and aligns with PRISMA guidelines. PubMed, Embase, and previous reviews were systematically searched. Follow-up studies from randomised trials of lifestyle interventions in pregnant women with obesity, which included offspring cardiac remodelling or related cardiovascular parameters as outcome measures, were included based on pre-defined inclusion criteria.
RESULTS: Eight studies from five randomised controlled trials were included after screening 3252 articles. Interventions included antenatal exercise (n = 2), diet and physical activity (n = 2), and preconception diet and physical activity (n = 1). Children were <2-months to 3-7-years-old, with sample sizes ranging between n = 18-404. Reduced cardiac remodelling, with reduced interventricular septal wall thickness, was consistently reported. Some studies identified improved systolic and diastolic function and a reduced resting heart rate. Risk of bias analyses rated all studies as 'fair' (some risk of bias). A high loss-to-follow-up was a common limitation.
CONCLUSION: Although there is some evidence to suggest that lifestyle interventions in women with obesity may limit offspring cardiac remodelling, further high-quality longitudinal studies with larger sample sizes are required to confirm these observations and to determine whether these changes persist to adulthood. Child offspring cardiovascular health benefits of preconception and antenatal lifestyle interventions in women with obesity.
<P>PROBLEM TO BE SOLVED: To obtain a cerebral function-improving agent which is useful for improving the functions and metabolisms of brains and treating and preventing the neuroses of the brains, such as the maintenance and improvement of memorizing and learning abilities and the mitigation of stresses, and is originated from safe and inexpensive natural products.  <P>SOLUTION: This cerebral function-improving agent is characterized by containing a phenylpentane compound such as a phenylpentanol compound, for example, 1-phenyl-3-pentanol, and a phenylpentanone compound, for example, 1-phenyl-3-pentanone. The cerebral function-improving agent has an action on promoting the release of dopamine, serotonin, or the like, in brains. The cerebral function-improving agent containing the compound as the active ingredient has a cerebral function-improving function based on the promotion of the release of the dopamine and/or the serotonin, and can be used as an improving agent for preventing or treating cerebral function diseases caused by the release disorders of the dopamine and/or the serotonin. The cerebral function-improving agent is originated from safe and inexpensive natural products, and can be administered in the form of a medicine, a food or a drink.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Participants randomized to letrozole group will take 5mg tablets orally daily for 5 days starting on day 3 of cycle. Dose can be adjusted up to 7.5mg based on ovulation response, maintained for subsequent cycles. Treatment continues for up to 6 ovulatory cycles or until pregnancy occurs. Ovulation assessed by follicular monitoring and progesterone. Compliance monitored by pill counts and diary. Routine antenatal care if pregnant. Adverse effects monitored per guidelines. Participants followed for multiple pregnancies. Tablets taken at same time each day. Maximum treatment period is 6 months.
The high-altitude pulmonary edema (HAPE) is the leading cause of death from high altitude sickness. At moderate altitude (2500-4500m) the incidence (0.2-6%) may be underestimated because only clinical HAPE leads to symptoms and motivates the patient to seek medical advice. Cremona et al. \[Cremona et al. Pulmonary extravascular fluid accumulation in recreational climbers: a prospective study. Lancet 2002;359:303-09\] suggested that a silent interstitial pulmonary edema arises in most recreational climbers at moderate altitude. Recently, chest sonography has been shown to effectively detect pulmonary edema and quantify extravascular lung water through the sign of "ultrasound lung comets" (ULCs) originating from water-thickened interlobular septa \[Lichtenstein D et al. The comet-tail artifact. An ultrasound sign of alveolar-interstitial syndrome. Am J Respir Crit Care Med;156:1640-46\]. The technique requires only basic twodimensional technology and has been applied in extreme, out-of-hospital setting, showing in recreational climbers a high prevalence of clinically silent interstitial pulmonary edema at high-altitude \[Pratali L et al. Frequent subclinical high-altitude pulmonary edema detected by chest sonography as ultrasound lung comets in recreational climbers. Crit Care Med 2010;38:1818-23\]. However, data for moderate altitude remain scarce, despite that mountaineers are increasing in age and comorbidities and could be more prone to high altitude emergencies.

Prospective, non-randomised, observational study. Study participants are recruited from a scientific research group lead by the Ohio State University during a glaciology study on the Ortles Glacier in South Tyrol (3905m).

Patients are tested for a baseline measure, during a permanent stay on the glacier camp (3h, 9h, 24h, 48h, 72h, 7d ). Parameters include chest ultrasound, Lake Louise score, cerebral sensitive score, non-invasive haemodynamic parameters (i.e. US) and markers of hypoxia responses, endothelial damage and inflammation.
BACKGROUND: As the COVID-19 pandemic shifts to an endemic phase, an increasing proportion of patients with cancer and a preoperative history of COVID-19 will require surgery. This study aimed to assess the influence of preoperative COVID-19 on postoperative risk for major adverse cardiovascular and cerebrovascular events (MACEs) among those undergoing surgical cancer resection. Secondary objectives included determining optimal time-to-surgery guidelines based on COVID-19 severity and discerning the influence of vaccination status on MACE risk.
STUDY DESIGN: National COVID Cohort Collaborative Data Enclave, a large multi-institutional dataset, was used to identify patients that underwent surgical cancer resection between January 2020 and February 2023. Multivariate regression analysis adjusting for demographics, comorbidities, and risk of surgery was performed to evaluate risk for 30-day postoperative MACE.
RESULTS: Of 204,371 included patients, 21,313 (10.4%) patients had a history of preoperative COVID-19. History of COVID-19 was associated with an increased risk for postoperative composite MACE as well as 30-day mortality. Among patients with mild disease who did not require hospitalization, MACE risk was elevated for up to 4 weeks after infection. Postoperative MACE risk remained elevated more than 8 weeks after infection in those with moderate disease. Vaccination did not reduce risk for postoperative MACE.
CONCLUSIONS: Together, these data highlight that assessment of the severity of preoperative COVID-19 infection should be a routine component of both preoperative patient screening as well as surgical risk stratification. In addition, strategies beyond vaccination that increase patients' cardiovascular fitness and prevent COVID-19 infection are needed.
BACKGROUND: Despite recent reports, the effectiveness of postoperative oral nutritional supplementation (ONS) on body weight loss and malnutrition after gastrectomy remains controversial. We aimed to elucidate the effectiveness of ONS especially in octogenarian patients undergoing oncological gastrectomy.
METHODS: A total of 286 consecutive patients who underwent gastrectomy for gastric cancer were eligible. Postoperative body weight loss, malnutrition, and sarcopenia were compared between patients with and without postoperative ONS among octogenarian patients aged ≥ 80 years and non-octogenarian patients aged < 80 years.
RESULTS: In this study, 36 (62.1%) octogenarian and 121 (53.1%) non-octogenarian patients continued postoperative ONS for three months. The clinicopathologic characteristics were not different between the ONS (-) and ONS (+) groups among the octogenarian and non-octogenarian patients. The changes in body weight and serum albumin levels at postoperative 1 year were different between the ONS (-) and ONS (+) groups (P = 0.03 and P = 0.04, respectively) among the octogenarian patients, but not between the two groups among the non-octogenarian patients (P = 0.99 and P = 0.29, respectively). Also, the decline in psoas muscle mass index at postoperative 6 months and 1 year was significantly lower in the ONS (+) group than in the ONS (-) group (P < 0.01 and P < 0.01, respectively). In addition, similar results were found in octogenarian patients who underwent distal gastrectomy.
CONCLUSIONS: Postoperative ONS could prevent body weight loss, malnutrition, and sarcopenia especially in octogenarian patients who underwent gastrectomy for gastric cancer.
Parathyroid hormone is an endogenous hormone with potent anabolic and catabolic actions in bone. It has recently been approved for the treatment of osteoporosis and is marketed as FORTEO by Eli Lilly and Company. Numerous studies in humans have validated its use to increase bone mineral density and prevent fractures. Interest has also surfaced in its potential application in the treatment of non-osteoporotic fractures and several animal studies have supported this local application. Little is known regarding its use in treating conditions of the oral cavity, but animal studies suggest that bones of the oral cavity are responsive to the anabolic actions of PTH. Furthermore, a recent study indicated that in a canine model, PTH was effective at reversing periodontal bone loss. Studies from our laboratory indicate that patients with hyperparathyroidism (HPT) do not have an increase in periodontal disease as measured by attachment levels. In fact, in our patient population there was an increase in osseous activity in patients with HPT in the form of tori and exostoses (bony protuberances in the oral cavity). This suggests that increased circulating levels of PTH do not adversely impact the oral cavity. Furthermore, in a wound healing animal model of bone regeneration, we found that regenerating intramembranous bone was more responsive to anabolic actions of PTH than endogenous bone of the vertebrae. These studies highlight the potential for PTH to positively impact osseous healing in the oral cavity in response to periodontal therapy.

The study will be double blinded, and patients will be randomized into one of two treatment groups (FORTEO or placebo once/daily). Patients will self-administer drug on a QD schedule, and take Vitamin D and Calcium, PO, QD, for six weeks. Drug administration will begin three days prior to periodontal surgery. Subjects will be followed at post-op, week 3, week 6, month 3, month 6, month 9, and month 12 visits. Clinical effects will be measured by serum collection, gingival crevicular fluid (GCF) sampling, standard dental radiographs, oral exam including perio probing, oral health quality of life questionnaire, and DEXA scans.